Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Protein biomarkers for the prediction of cardiovascular disease in type 2 diabetes

In English

Författare

  • Helen C. Looker
  • Marco Colombo
  • Felix Agakov
  • Tanja Zeller
  • Leif Groop
  • Barbara Thorand
  • Colin N. Palmer
  • Anders Hamsten
  • Ulf de Faire
  • Everson Nogoceke
  • Shona J. Livingstone
  • Veikko Salomaa
  • Karin Leander
  • Nicola Barbarini
  • Riccardo Bellazzi
  • Natalie van Zuydam
  • Paul M. McKeigue
  • Helen M. Colhoun
Visa allt

Summary, in English

Aims/hypothesis We selected the most informative protein biomarkers for the prediction of incident cardiovascular disease (CVD) in people with type 2 diabetes. Methods In this nested case-control study we measured 42 candidate CVD biomarkers in 1,123 incident CVD cases and 1,187 controls with type 2 diabetes selected from five European centres. Combinations of biomarkers were selected using cross-validated logistic regression models. Model prediction was assessed using the area under the receiver operating characteristic curve (AUROC). Results Sixteen biomarkers showed univariate associations with incident CVD. The most predictive subset selected by forward selection methods contained six biomarkers: N-terminal pro-B-type natriuretic peptide (OR 1.69 per 1 SD, 95% CI 1.47, 1.95), high-sensitivity troponin T (OR 1.29, 95% CI 1.11, 1.51), IL-6 (OR 1.13, 95% CI 1.02, 1.25), IL-15 (OR 1.15, 95% CI 1.01, 1.31), apolipoprotein C-III (OR 0.79, 95% CI 0.70, 0.88) and soluble receptor for AGE (OR 0.84, 95% CI 0.76, 0.94). The prediction of CVD beyond clinical covariates improved from an AUROC of 0.66 to 0.72 (AUROC for Framingham Risk Score covariates 0.59). In addition to the biomarkers, the most important clinical covariates for improving prediction beyond the Framingham covariates were estimated GFR, insulin therapy and HbA(1c). Conclusions/interpretation We identified six protein biomarkers that in combination with clinical covariates improved the prediction of our model beyond the Framingham Score covariates. Biomarkers can contribute to improved prediction of CVD in diabetes but clinical data including measures of renal function and diabetes-specific factors not included in the Framingham Risk Score are also needed.

Publiceringsår

2015

Språk

Engelska

Sidor

1363-1371

Publikation/Tidskrift/Serie

Diabetologia

Volym

58

Issue

6

Dokumenttyp

Artikel i tidskrift

Förlag

Springer

Ämne

  • Cardiac and Cardiovascular Systems
  • Endocrinology and Diabetes

Nyckelord

  • Cardiovascular diseases
  • Epidemiology
  • Protein biomarkers
  • Risk factors
  • Type 2 diabetesmellitus

Status

Published

Forskningsgrupp

  • Genomics, Diabetes and Endocrinology

ISBN/ISSN/Övrigt

  • ISSN: 1432-0428